The New and Non-Transparent Cancer Drugs Fund Eifiona M. WoodDyfrig A. Hughes Commentary 12 December 2019 Pages: 1 - 4
Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians Alisa LikhitsupNeehar D. Parikh Review Article 01 October 2019 Pages: 5 - 24
Economic Burden of Anxiety Disorders: A Systematic Review and Meta-Analysis Alexander KonnopkaHannah König Systematic Review 24 October 2019 Pages: 25 - 37
A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA Elizabeth WehlerNatalie BoytsovStacey Kowal Original Research Article Open access 27 August 2019 Pages: 39 - 56
Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study Dean A. RegierDavid L. VeenstraJosh J. Carlson Original Research Article 06 September 2019 Pages: 57 - 68
Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan Luis HernandezHiroyo KuwabaraRyuichi Iwakiri Original Research Article Open access 24 September 2019 Pages: 69 - 84
Bayesian Hierarchical Models for Meta-Analysis of Quality-of-Life Outcomes: An Application in Multimorbidity Susanne SchmitzTatjana T. MakovskiMaurice P. Zeegers Original Research Article 04 October 2019 Pages: 85 - 95
Evaluating Partitioned Survival and Markov Decision-Analytic Modeling Approaches for Use in Cost-Effectiveness Analysis: Estimating and Comparing Survival Outcomes Caitlin SmareKhalid LakhdariSukhvinder Johal Original Research Article Open access 19 November 2019 Pages: 97 - 108
The Value of Shorter Initial Opioid Prescriptions: A Simulation Evaluation Margrét V. BjarnadóttirDavid R. AndersonD. Alan Nelson Original Research Article 21 October 2019 Pages: 109 - 119
Comment on: ‘NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence’ Livio GarattiniNicholas Freemantle Letter to the Editor 17 December 2019 Pages: 121 - 122
Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA Elizabeth WehlerNatalie BoytsovStacey Kowal Correction Open access 12 November 2019 Pages: 123 - 123